STOCKHOLM, June 30, 2020 /PRNewswire/ -- Oncopeptides AB
(Nasdaq Stockholm, ONCO) today announces that the number of shares
and votes in Oncopeptides has changed as a result of exercise of
warrants under the company's incentive programs.
Through the exercise of warrants under the company's incentive
programs, the number of outstanding shares and votes have increased
by 21,266 from 61,478,417 to 61,499,683. The share capital has
increased by approximately SEK 2,363
from SEK 6,830,935 to SEK 6,833,298.
The information in the press release is information that
Oncopeptides is obliged to make public pursuant to the Swedish
Financial Instruments Trading Act. The information was submitted
for publication, through the agency of the contact persons above,
on June 30, 2020 at
14.00 (CEST).
About Oncopeptides
Oncopeptides is a pharmaceutical company focused on the
development of targeted therapies for difficult-to-treat
hematological diseases. The company is focusing on the development
of the lead product candidate melflufen, a first-in-class
aminopeptidase-targeting peptide-drug conjugate that rapidly
delivers an alkylating payload into tumor cells. Melflufen is in
development as a new treatment for the hematological malignancy
multiple myeloma and is currently being tested in multiple clinical
studies including the pivotal phase 2 HORIZON study and the ongoing
phase 3 OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden with its U.S. headquarters
in Boston, Mass. The company is
listed in the Mid Cap segment on Nasdaq Stockholm with the ticker
ONCO.
For more information visit
www.oncopeptides.com.
For further information, please contact:
Jakob Lindberg, CEO of
Oncopeptides
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46 8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
E-mail: rein.piir@oncopeptides.com
Cell phone: +46 70 853 72 92
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/oncopeptides-ab/r/number-of-shares-and-votes-in-oncopeptides,c3145109
The following files are available for download:
https://mb.cision.com/Main/15404/3145109/1272096.pdf
|
Press release -
Number of shares and votes in Oncopeptides
|